Login to Your Account



Olesoxime Fails in Pivotal Trial, Actelion's Trophos Buy Nixed

By Cormac Sheridan
BioWorld Today Correspondent

Wednesday, December 14, 2011
Actelion AG's potential acquisition of Trophos SA is off the table, following the failure of the latter firm's lead drug olesoxime to demonstrate efficacy in a pivotal Phase III trial in amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription